Company Profile
Taysha Gene Therapies Stock Price, News & Analysis
- Ticker:
- TSHA
- Exchange:
- NASDAQ
- Sector:
- Biotechnology
- Location:
- United States
Stock performance
5.38 USD (-15.14%)
Close
Last updated: July 13, 2026 at 00:00
1.82B USD
Market cap
Why the stock is moving
TSHA is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Company overview
Business overview
Taysha Gene Therapies is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Taysha Gene Therapies is followed within the biotech universe for its exposure to catalyst-driven execution.
Business Model Characteristics
Taysha Gene Therapies follows a catalyst-driven model where the market watches how the company turns development work into repeatable value creation.
Position Within the Biotechnology Landscape
Compared with more mature healthcare peers, Taysha Gene Therapies sits closer to the development side of the biotechnology landscape, where timing around data and approvals matters most.
Future catalysts
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
Zimmer Biomet Names Chintan Desai President of Asia Pacific Region
ZBH · Source: Zimmer Biomet
- 02
Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results
ZBH · Source: Zimmer Biomet
- 03
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma
BMY · Source: BMYBristol-Myers Squibb Company
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Taysha Gene Therapies (TSHA)?
Taysha Gene Therapies (TSHA) most recently closed at 5.38 USD, a -15.14% move versus the previous session.
What is the market cap of Taysha Gene Therapies (TSHA)?
Taysha Gene Therapies currently has a market capitalization of 1.82B USD on BioPharmSignal.
What does Taysha Gene Therapies do?
Taysha Gene Therapies is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
On which exchange is TSHA stock listed?
Taysha Gene Therapies (TSHA) is associated with NASDAQ, United States, Biotechnology.
What is Taysha?
Taysha Gene Therapies is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs.
Which conditions is Taysha Gene Therapies targeting with Taysha?
Taysha Gene Therapies is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
What is Gene?
Taysha Gene Therapies is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs.
What is Therapies?
Taysha Gene Therapies is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs.